Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA inspected Rose Acre Farms last month and the company is taking corrective action. FDA is monitoring to ensure the appropriate action takes place. https://t.co/JnRtLB9ZMN
SteveFDA (R-D.C.)
@SGottliebFDA
Federal health officials updated consumer advice today because it is highly unlikely that romaine lettuce from the Yuma growing region is still in the supply chain: https://t.co/We02xgGjGj
SteveFDA (R-D.C.)
@SGottliebFDA
FDA & CDC remind consumers to not eat any of the recalled eggs from Rose Acre Farms. These eggs were recalled April 13 & 16 so stores should not have them for purchase. Eggs last about three weeks - consumers should check they don’t have recalled
SteveFDA (R-D.C.)
@SGottliebFDA
We know romaine lettuce has not been shipped from the Yuma area since mid-April. Consumers can be confident that romaine currently available for purchase is not part of this outbreak investigation: https://t.co/We02xgGjGj
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA ruled out that the contamination was caused by just one farm suggesting it was a complex problem and will take further time to investigate https://t.co/We02xgGjGj Our goal is to find the source of this outbreak. We’ll use what we learn to improve our
SteveFDA (R-D.C.)
@SGottliebFDA
RT @HHSMedia: HHS @SecAzar praises @US_FDA approval of first non-opioid treatment for opioid withdrawal https://t.co/x7R2uATqCb #opioids
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is taking policy steps to help promote the development of new treatments for opioid addiction, to promote the use of MAT, and to address the stigma sometimes associated with safe and effective replacement therapy. Stigma can be a barrier to their use
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAWomen: Read @SGottliebFDA's full remarks from today's #FDAGreatDebate: https://t.co/pUZoZBY1G1
SteveFDA (R-D.C.)
@SGottliebFDA
RT @ABC: "We will never see his like again": 81-year-old whose blood donations have helped save over 2 million babies donate… https://t.co/M85PMSwBFR
SteveFDA (R-D.C.)
@SGottliebFDA
RT @NIIMBL: @US_FDA Deputy Commissioner for Policy, Legislation, and Analysis, Anna Abram, discusses FDA support for the develo… https://t.co/WTPoYOc4fr
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: Today, FDA sent official information requests to four e-cig manufacturers. The companies must respond by July 12… https://t.co/pvFKvkSiJr
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: FDA requires additional e-cigarette makers to provide critical information so the agency can better examine youth u… https://t.co/9kMGpEpGiZ
SteveFDA (R-D.C.)
@SGottliebFDA
@alikodjakNPR @sangerkatz @PeterSullivan4 @porszag @SecAzar But our discussion was about Part D. In Part D people choose plans in a large marketplace. Even in the employer ASO market there’s choice. True sometimes employers only offer a single option, but
SteveFDA (R-D.C.)
@SGottliebFDA
The letters to more e-cigarette makers follow a similar request #FDA sent to JUUL Labs last month. We’ll explore all regulatory options, including enforcement actions, based on what we learn from the information these manufacturers are required to provide
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from @SGottliebFDA on new agency efforts to shine light on situations where drug makers may be pursuing g… https://t.co/pmd86YTlgb
SteveFDA (R-D.C.)
@SGottliebFDA
Too many kids continue to experiment with e-cigarette and vaping products, and it’s critical that we take aggressive steps to address it. This includes taking a hard look at whether certain design features/product marketing practices are fueling youth use
SteveFDA (R-D.C.)
@SGottliebFDA
Today #FDA is continuing to take important steps under our Youth Tobacco Prevention Plan by requiring four additional e-cigarette makers to provide critical information so the agency can better examine youth use and product appeal: https://t.co/KdVzyo6YbU
SteveFDA (R-D.C.)
@SGottliebFDA
@alikodjakNPR @sangerkatz @PeterSullivan4 @porszag @SecAzar The bigger change we’ve seen in recent years, IMHO, is the wider adoption of “closed” formularies. I don’t have data but am pretty sure they’re far more common today than they were pre-ACA, even
SteveFDA (R-D.C.)
@SGottliebFDA
We’ll continue to take vigorous steps under #FDA’s Youth Tobacco Prevention Plan, using the full scope of our authorities, to target youth access to, and appeal of, these products. It’s a top priority of ours to prevent kids from getting hooked on nicotin